bellus health press release
Get the hottest stocks to trade every day before the … Press Release reported on 12/14/20 that BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus … 02/25/2021 16:01. BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tre The company’s stock price has collected 5.03% of gains in the last five trading sessions. BELLUS Health Inc.275 Armand-Frappier Blvd.Laval, QuebecCanada H7V 4A7, Tel. March 23, 2020 GMT. Press Releases Year. Press Release reported on 02/25/21 that BELLUS Health Reports Year 2020 Financial Results and Business Highlights. BELLUS Health (BLU): FY GAAP EPS of -$0.54 misses by $0.01.Revenue of $15kCash, cash equivalents and short-term investments of $98.3M.Press Release Dive Insight: Monday's announcement might have taken Bellus investors by surprise. 3.9400 0.00 (0.00%)Pre-Market: 7:00AM EST, Subscribe to Premium to view Fair Value for BLU. BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or … BELLUS Health Establishes At-the-Market Facility LAVAL, Quebec--(Business Wire)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health… BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences LAVAL, Quebec--(Business Wire)--BELLUS Health Inc. … The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. Press Release Feb 22, 2021 12:00 UTC. LAVAL, Quebec — BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2019. The AP news staff was not involved in its creation. About BELLUS Health (www.bellushealth.com) BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS Health Inc. (NASDAQ:BLU) went down by -4.97% from its latest closing price compared to the recent 1-year high of $12.03. BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus, BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment, BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference, BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences, BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019, BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences, BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients, BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan. Press Releases. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences. Original press release here – BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due – – 4.77 million BELLUS Health common shares to be issued in consideration – LAVAL, Quebec–(BUSINESS WIRE)–Mar. April 29, 2010 – BELLUS Health … BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020. Currency in USD, Trade prices are not sourced from all markets. The MarketWatch News Department was not involved in the creation of this content. CONTACT: Danny Matthews. : (450) 680-4500Fax: (450) 680-4501info@bellushealth.com. BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today presented its 2018 achievements and corporate priorities for 2019. Last month, Jefferies hosted an investor call with a cough specialist who, according to the investment bank, expected the Phase 2 study to read out positive and show efficacy data "as good as" Merck's gefapixant, which works in a similar way to Bellus' drug. LAVAL, Quebec--(BUSINESS WIRE)--Mar 23, … Press release content from Business Wire. January 14, 2021 GMT. Research Reports. Detailed price information for Bellus Health Inc (BLU-T) from The Globe and Mail including charting and trades. * Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals * Bellus Health Inc - deal for total consideration of CA$2.7 million 2/25/21 ... 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related … BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the "Company" or "BELLUS Health"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in … BELLUS Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutic The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life.